Inventages (a global healthcare venture capital fund backed by Nestlé)
announced today that they are working with SAP AG to integrate a
comprehensive and mechanism-based approach to disease management with
best-in-class IT frameworks to develop the next generation of
personalized medicine companies.
Personalized medicine uses genetic and non-genetic information, such as
environmental factors, to individualize the prevention, diagnosis, and
treatment of disease. However to date, these solutions have typically
been fragmented and incomplete, only addressing a subset of influencing
factors. The personalized medicine solutions of the future will be
holistic; integrating a patient’s genomic information, medical history,
environmental and lifestyle factors. This holistic approach to managing
disease will require the integration of multiple data sources and the
structuring and analysis of large data volumes. This capability will be
a key differentiator in ensuring the success and longevity of a
personalized medicine solution.
This collaboration between a global healthcare venture capital fund and
one of the world’s leading IT companies aims to provide emerging
healthcare companies with both capital and extensive expertise and
resources. The collaboration plans to leverage Inventages’ experience in
developing highly efficacious clinically validated products and SAP’s
expertise in building and operating complex IT platforms and ecosystems.
“Inventages has been looking at personalized medicine for several years
and consequently we recognize that the future of disease management
needs to be holistic; all of the factors that influence a patient’s
health need to be considered. Inventages and SAP are aligned in their
vision to advance personalized medicine through the use of information
technology. This collaboration plans to provide our companies with
access to SAP’s unique capabilities and resources in mobile, cloud and
big data processing,” said Dr Gunnar Weikert, Chairman and Managing
Partner of Inventages.
“We are excited about this opportunity to collaborate with Inventages
and Nestlé, and combine our complementary capabilities in healthcare and
IT,” said Dr. Stefan Sigg, senior vice president, SAP HANA®, SAP AG.
”Inventages and Nestlé bring deep unbiased expertise in healthcare
technology development including the design and running of clinical
trials, as well as navigation of the complex regulatory and
reimbursement environments. We are confident that this collaboration
will help to identify and develop innovative healthcare solutions with
the goal of improving people’s lives.”
Inventages is a global healthcare venture capital fund backed by Nestlé
Investments are focused on highly effective, safe therapeutics and
technologies that stand to radically improve the practice of medicine.
Particular areas of focus are chronic diseases such as
gastrointestinal disease, brain health, and metabolic disease, which
constitute the major burden on healthcare systems, as well as
pediatrics, critical care and aging.
# # #
SAP and all SAP logos are trademarks or registered trademarks of SAP AG
in Germany and in several other countries.
All other product and service names mentioned are the trademarks of
their respective companies.
SAP Forward-looking Statement
Any statements contained in this document that are not historical facts
are forward-looking statements as defined in the U.S. Private Securities
Litigation Reform Act of 1995. Words such as “anticipate,” “believe,”
“estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,”
“predict,” “should” and “will” and similar expressions as they relate to
SAP are intended to identify such forward-looking statements. SAP
undertakes no obligation to publicly update or revise any
forward-looking statements. All forward-looking statements are subject
to various risks and uncertainties that could cause actual results to
differ materially from expectations The factors that could affect SAP's
future financial results are discussed more fully in SAP's filings with
the U.S. Securities and Exchange Commission ("SEC"), including SAP's
most recent Annual Report on Form 20-F filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of their dates.